Accepted 5 July 2021
Available Online 16 July 2021
improved clinical outcome
Remdesivir is a broad spectrum antiviral agent meant to inhibit viral RNA polymerases against members of several virus families, including filoviruses. Although reported for significant clinical improvements in COVID-19, a detailed observation of the connection with the drawbacks of remdesivir therapy was poor pulmonary distribution and hepatotoxicity (transaminase elevation) was recorded that resulted in discontinuation of remdesivir therapy. Nanodrug delivery facilitates a large drug payload to the targeted site improving the efficacy. With the lesser dose administered, could be expected for minimized adverse events. Additional payload of ashwagandha will protect the liver from the damages caused if any. Remdesivir in nanoformulation may be a safe and an effective therapeutic agent for COVID 19 when co-adminstered with ashwagandha.
- © 2021 The Authors. Published by Atlantis Press B.V.
- Open Access
- This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
Cite This Article
TY - JOUR AU - R. Velmurugan AU - P. Manoj Kumar AU - Keerthi G.S. Nair PY - 2021 DA - 2021/07/16 TI - Nebulizer, Inhaled Remdesivir Nanoparticle Co-administered with Withania Somnifera may Minimize the Hepatotoxicity in COVID-19 JO - Materials Highlights SP - 68 EP - 70 VL - 2 IS - 3 SN - 2666-4933 UR - https://doi.org/10.2991/mathi.k.210708.001 DO - https://doi.org/10.2991/mathi.k.210708.001 ID - Velmurugan2021 ER -